Maria Daniela Bergamasco

Dr. Maria Daniela Bergamasco

Universidade Federal de Sao Paulo, Brazil
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2011 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
Maria Daniela BergamascoMaria Daniela Bergamasco
Maria Daniela Bergamasco
MBM. Barroso Barbosa
M. Barroso Barbosa
DGD. de Oliveira Garcia
D. de Oliveira Garcia
RCR. Cipullo
R. Cipullo
JMJ.C.M. Moreira
J.C.M. Moreira
CAC.S. Abboud
C.S. Abboud

23 July 2021 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
Maria Daniela BergamascoMaria Daniela Bergamasco
Maria Daniela Bergamasco
CPCarlos Alberto P. Pereira
Carlos Alberto P. Pereira
CACelso Arrais-Rodrigues
Celso Arrais-Rodrigues
DFDiogo B. Ferreira
Diogo B. Ferreira
OBOtávio Cesar Baiocchi
Otávio Cesar Baiocchi
Arnaldo L. ColomboArnaldo L. Colombo
Arnaldo L. Colombo
Patients with hematologic malignancies and hematopoietic cell transplant recipients (HCT) are at high risk for invasive fungal disease (IFD). The practice of antifungal prophylaxis with mold-active azoles has been challenged recently because of drug–drug interactions with novel targeted therapies. This is a retrospective, single-center cohort study of consecutive cases of proven or probable IFD, diagnosed between 2009 and 2019, in adult hematologic patients and HCT recipients managed with fluconazole prophylaxis and an antifungal diagnostic-driven approach for mold infection. During the study period, 94 cases of IFD occurred among 664 hematologic patients and 316 HCT recipients. The frequency among patients with allogeneic HCT, autologous HCT, acute leukemia and other hematologic malignancies was 8.9%, 1.6%, 17.3%, and 6.4%, respectively. Aspergillosis was the leading IFD (53.2%), followed by fusariosis (18.1%), candidiasis (10.6%), and cryptococcosis (8.5%). The overall 6-week mortality rate was 37.2%, and varied according to the host and the etiology of IFD, from 28% in aspergillosis to 52.9% in fusariosis. Although IFD occurred frequently in our cohort of patients managed with an antifungal diagnostic driven approach, mortality rates were comparable to other studies. In the face of challenges posed by the use of anti-mold prophylaxis, this strategy remains a reasonable alternative.

1 October 2012 in Transplantation Proceedings
Verified
Journal Article
Closed access
CAC.S. Abboud
C.S. Abboud
Maria Daniela BergamascoMaria Daniela Bergamasco
Maria Daniela Bergamasco
CBC.E.S. Baía
C.E.S. Baía
MLM.P. Lallée
M.P. Lallée
AZA.S.C. Zan
A.S.C. Zan
SMS. Mies
S. Mies

26 December 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
VOVitor Falcão de Oliveira
Vitor Falcão de Oliveira
JPJoão Antonio Gonçalves Garreta Prats
João Antonio Gonçalves Garreta Prats
VBValdes Roberto Bollela
Valdes Roberto Bollela
APAlessandro C. Pasqualotto
Alessandro C. Pasqualotto
DFDiego Rodrigues Falci
Diego Rodrigues Falci
Arnaldo L. ColomboArnaldo L. Colombo
Arnaldo L. Colombo
Background: Data on clinical characteristics and prognosis of chronic pulmonary aspergillosis (CPA) in resource-limited, high tuberculosis (TB) burden settings, especially in Brazil, remain scarce. Methods: This multicenter retrospective study evaluated all CPA cases diagnosed between 2012 and 2018 across eight centers in Brazil, examining clinical presentation, diagnosis, treatment, mortality, and factors associated with death, including differences related to pulmonary TB. To identify independent predictors of mortality, we conducted multivariate Cox regression. One-year mortality was analyzed using Kaplan–Meier survival curves. Results: A total of 191 CPA cases were diagnosed, with a median age of 50 years (IQR 40–59) and 62% were male. TB was the most frequent predisposing condition (n = 138, 72%). Most patients (80%) received antifungal therapy, primarily itraconazole (n = 140, 73%). Surgery was performed in 34% of cases. According to Kaplan–Meier analysis, the cumulative mortality at 12 months was 6%. Compared to survivors, nonsurvivors had significantly lower rates of TB (52% vs 77%, P = .019) and higher rates of malignancies (13% vs 3%, P = .033). In multivariate analysis, only TB was independently associated with lower mortality (HR 0.413, 95% CI: .179–.954, P = .038). The TB group showed more hemoptysis (P = .008) and greater radiological involvement, suggesting delayed diagnosis. Conclusions: In Brazil, the mortality of CPA was lower compared with that reported in previous studies, particularly among patients with TB. In TB-endemic, resource-limited settings, overlapping clinical and radiological features may delay diagnosis and antifungal treatment.